Background. Orthopaedic surgeons are increasingly pressured to consider thromboprophylaxis for patients when little evidence exists. The aim of this study was to determine the incidence of fatal pulmonary embolism following office attendance in our outpatient fracture clinic. Methods. Between October 2004 and September 2006 details of all new patients referred to our orthopaedic fracture clinic were prospectively entered into an audit database. Patients did not receive any form of thromboprophylaxis. Data was cross referenced with a national mortality database to identify all patients who subsequently died within 90 days of attendance in fracture clinic. Results. 11,502 new patient fracture clinic appointments occurred during the study period. 5604 patients had lower limb injuries. Twenty three patients died within 90 days of being seen. The mean age of these patients was 75 years (range 52–100). Two of the 23 patients attended fracture clinic with lower limb injuries. Review of the medical records showed no evidence of pulmonary embolism. Assuming a worst case scenario that both died of fatal pulmonary embolism the incidence of fatal pulmonary embolism following attendance in fracture clinic with a lower limb injury is no higher than 0.036% (95% CI 0.09%–0.33%). Conclusion. The incidence of fatal PE following outpatient management of lower limb fractures is very low. This incidence data will inform decisions on the risk-benefit analyisis of thromboprophylaxis in this group of patients

Fatal pulmonary embolism (PE) after total hip replacement (THR) is a major concern to all orthopaedic surgeons. Our intention was to ascertain death rates and deaths due to PE following total hip replacement where chemical thromboprophylaxis was not used routinely. We determined retrospectively, the postoperative mortality and fatal pulmonary embolism rates in 1671 consecutive primary total hop replacements in 1547 patients performed as staged procedures between January 1997 and April 2000 at an orthopaedic hospital. The minimum follow-up period was six weeks period after surgery at an orthopaedic hospital. Patients were traced by questionnaires, outpatient appointments and by telephone. Post-mortem records were used to verify cause of death. Follow-up was 100%. The death rate from PE was 0. 12% (CI 0. 03% – 0. 44%) and the all-cause mortality rate was 0. 36% (CI 0. 16% – 0. 78%). All deaths were within the first 10 days during the initial hospital stay. The patient mortality was compared with the population mortality for England and Wales, using standardised mortality ratios (SMRs). The SMR for both sexes combined was 0. 81. We observed a lower mortality in females (SMR=0. 43) but a higher mortality in males (SMR=1. 44) during the first 42 postoperative days compared to the general population. Fatal PE after THR without routine chemical thromboprophylaxis is very uncommon. The death rate in patients undergoing THR appears to be lower than that in the general population

Aim: To determine retrospectively the post-operative mortality and fatal pulmonary embolism (PE) rates in 936 consecutive primary total knee replacements (TKR) in the three month period after surgery where chemical thromboprophylaxis was not routinely used. Methods: Operations were performed over a period of eleven years by eight different senior orthopaedic surgeons on 248 men and 525 women. One hundred and sixty three patients had bilateral TKRs and the mean age at the time of operation was similar (69.4 and 72.2 years respectively). Patients were traced by out-patient appointments, telephone and through their general practitioners (GPs). Post-mortem examinations were used to verify cause of death in all save three of the cases. All but one of the patients were followed up. Results: There were no deaths from PE confirmed by post-mortem examinations. As three patients were certified dead without post-mortem examination and one patient could not be traced this meant that, at worst, our fatal PE rate was 0.43% (4/936; CI 0.14%–1.17%). The all-cause mortality rate was 0.64% (6/936; CI 0.26%–0.46%) (Table 1). The patient mortality was compared with the population mortality of England and Wales using standardised mortality ratios (SMRs). The SMR for both sexes combined was 0.74 (CI 0.29–1.52). We observed a lower mortality in females SMR = 0.67 and males SMR = 0.84 during the first three post-operative months than compared to the general population. Conclusion: Fatal pulmonary embolism after total knee replacement without routine chemical thromboprophylaxis is uncommon. The overall death rate in this series of patients undergoing total knee replacement appears to be lower than that in the general population

Aim. To assess the incidence of fatal pulmonary embolism (PE) following elective total knee replacement (TKR) with a standardised multi-modal prophylaxis regime in a large teaching DGH over a 10 year period. Material and methods. Information was gathered from a prospective audit database, utilising clinical coding for TKR and those that had died within 42 and 90 days. The 10 years from April 2000 were analysed to establish both 42 and 90 day mortality rates. A multi-modal prophylaxis regime for all patients included regional anaesthesia (when possible), mechanical prophylaxis (Flo-tron calf garment per-operatively, AV impulse boots until mobile and anti-embolism stockings for 6 weeks), mobilisation within 24 hours and 75mg aspirin for 4 weeks. A case note review was performed to ascertain the causes of death. Where a patient had been referred to the coroner, the coroner's office was contacted for PM results. Results. There were 6,584 cases; the mortality rates at 42 and 90 days were 0.36 and 0.52%. There were no fatal PE's within 42 days of surgery. 2 fatal PE's occurred subsequently at 48 and 57 days (0.03%) The leading causes of death were myocardial infarction and cerebro-vascular accident. Conclusion. Fatal pulmonary embolus following elective TKR with a multi-modal prophylaxis regime is not a significant cause of mortality

In order to prevent fatal pulmonary embolism TED stockings, foot pumps and early mobilisation on the second post-operative day are used at our centre. Only patients deemed to be high risk (previous DVT/PE or obese) are given Clexane as an inpatient and Warfarin for six weeks post op. 1137 primary hips and 1017 primary knees were identified using the hospital database and the figures confirmed with the theatre implant order books. Those patients now deceased on the database had their death certificates obtained from the coroner. No patients had died from pulmonary embolism within three months post operation. 34 patients had been discharged on Warfarin according to the pharmacy records. We would therefore not recommend the routine use of chemical thromboprophylaxis following joint replacement

Aims. Thromboprophylaxis following Total Hip Replacement (THR) surgery remains controversial, balancing VTE prevention against wound leakage and subsequent deep infection. We analysed the 90 day cause of death post THR in our institution after the implementation of new thromboprophylactic policy of low dose aspirin for low risk patients, as part of a multimodal regime. Those at high risk were anticoagulated. Patients and methods. The PAS database was used to identify patients undergoing primary THR between January 2012 and June 2017 at The Royal Derby Hospital, and all deaths within 90 days. Trauma cases were excluded. Case note review and Coroner's verdict were utilised to ascertain cause of death. Results were compared to a previous study at the same institution prior to the introduction of the new policy, where thromboprophylaxis was decided upon by surgeon preference for either LMWH, aspirin or warfarin. Results. During this period 4021 THRs were performed. The rate of mortality was 0.22% at 90 days. This compares to 0.58% in the previous study with the only other factor changing being the rapidity of post op mobilization. Of the 9 deaths, only one was due to fatal pulmonary embolism. None of the deaths were at high risk of VTE. This compared to 5 fatal pulmonary embolism deaths in1838 patients in the previous study in the LMWH group. The leading causes of death were heart failure and lower respiratory tract infection. Conclusion. Our institution reports a similar 90 day (0.22%) mortality using aspirin to that in the last 5 years on the NJR (0.3%) in which over 80% use LMWH. We confirm that fatal PE following elective THR with a multi-modal prophylaxis regime is rare. Changing to low dose aspirin in low risk patients is a safe option

In response to the recent publication in April 2007 of NICE guidelines on venous thromboembolism, we report our practice and experience of VTE in adult hip and knee arthroplasty. It is generally agreed that the 2 major complications of VTE are sudden death as a result of pulmonary embolism and post thrombotic syndrome. NICE guidelines make 2 assumptions:. That chemical and mechanical prophylaxis can reduce these complications. That Orthopaedic surgery, in particular elective Primary Joint Replacements are particularly high risk procedures with respect to these 2 complications. We have studied a large cohort of patients who had Aspirin only as chemical prophylaxis to determine the incidence of clinical thromboembolism before and after discharge and the mortality from PE at 90 days. We performed a prospective analysis of consecutive patients undergoing primary total knee and hip replacement from November 2002 to November 2007. In total 2050 patients had total knee replacement and 2203 patients had total hip replacement. All patients were treated at one specialist centre under the care of one surgeon. Data was complete and accurate for all patients at 90 days post-operatively. Standard practice was the use of 150mg Aspirin from Day 1 post-operatively for a total of six weeks combined with spinal anaesthesia and early mobilisation. The overall rate for Fatal Pulmonary embolism 0.07% (3/4253), overall death rate 0.3%(13/4253), for treated non-fatal PE 0.66% (28/4253) and for treated above knee DVT was 0.33%(14/4253). Our data suggests that fatal pulmonary embolism is not common and does not account for most deaths following total hip and knee arthroplasty. We suggest there is no evidence that chemical/mechanical prophylaxis reduces the risk of sudden death from PE following elective primary joint replacement and with modern surgical practice elective hip and knee replacement should no longer be considered high risk procedures

In response to the recent publication in April 2007 of NICE guidelines on venous thromboembolism, we report our practice and experience of VTE in adult hip and knee arthroplasty. It is generally agreed that the 2 major complications of VTE are sudden death as a result of pulmonary embolism and post thrombotic syndrome. NICE guidelines make 2 assumptions:. That chemical and mechanical prophylaxis can reduce these complications. That Orthopaedic surgery, in particular elective Primary Joint Replacements are particularly high risk procedures with respect to these 2 complications. We have studied a large cohort of patients who had Aspirin only as chemical prophylaxis to determine the incidence of clinical thromboembolism before and after discharge and the mortality from PE at 90 days. We performed a retrospective analysis of consecutive patients undergoing primary total knee and hip replacement from November 2002 to November 2007. In total 2050 patients had total knee replacement and 2203 patients had total hip replacement. All patients were treated at one specialist centre under the care of one surgeon. Data was complete and accurate for all patients at 90 days post-operatively. Standard practice was the use of 150mg Aspirin from Day 1 post-operatively for a total of six weeks combined with spinal anaesthesia and early mobilisation. The overall rate for Fatal Pulmonary embolism 0.07% (3/4253), overall death rate 0.31%(13/4253), for treated non-fatal PE 0.66% (28/4253) and for treated above knee DVT was 0.33%(14/4253). Our data suggests that fatal pulmonary embolism is not common and does not account for most deaths following total hip and knee arthroplasty. We suggest there is no evidence that chemical/mechanical prophylaxis reduces the risk of sudden death from PE following elective primary joint replacement and with modern surgical practice elective hip and knee replacement should no longer be considered high risk procedures

Following the recent publication in April 2007 of NICE guidelines on venous thromboembolism, we report our practice and experience of VTE in adult hip and knee arthroplasty. It is generally agreed that the 2 major complications of VTE are sudden death as a result of pulmonary embolism and post thrombotic syndrome. NICE guide-lines make 2 assumptions:. That chemical and mechanical prophylaxis can reduce these complications. That Orthopaedic surgery, in particular elective Primary Joint Replacements are particularly high risk procedures with respect to these 2 complications. Methods and Results: We have studied a large cohort of patients who had Aspirin only as chemical prophylaxis to determine the incidence of clinical thromboembolism before and after discharge and the mortality from PE at 90 days. We performed a retrospective analysis of consecutive patients undergoing primary total knee and hip replacement from November 2002 to November 2007. In total 2050 patients had total knee replacement and 2203 patients had total hip replacement. All patients were treated at one specialist centre under the care of one surgeon. Data was complete and accurate for all patients at 90 days post-operatively. Standard practice was the use of 150mg Aspirin from Day 1 post-operatively for a total of six weeks combined with spinal anaesthesia and early mobilisation. The overall rate for Fatal Pulmonary embolism 0.07% (3/4253), overall death rate 0.31%(13/4253), for treated non-fatal PE 0.66% (28/4253) and for treated above knee DVT was 0.33%(14/4253). Conclusion: Our data suggests that fatal pulmonary embolism is not common and does not account for most deaths following total hip and knee arthroplasty. We suggest there is no evidence that chemical/mechanical prophylaxis reduces the risk of sudden death from PE following elective primary joint replacement and with modern surgical practice elective hip and knee replacement should no longer be considered high risk procedures

Elderly patients undergoing surgery for a hip fracture are at risk of thromboembolic events (TEV). The risk of TEV is now rare due to thromboprophylaxis. However, hip fracture treatment has evolved over the last decade. The risk of TEV may have been modified. The objective of this study was to determine the risk of symptomatic TEV following surgery for a hip fracture, in an elderly population. Retrospective cohort study of all patients > 65 years old undergoing surgery for a femoral neck or intertrochanteric hip fracture in two academic centers, between January 1st 2008 and January 1st 2019. The follow-up was fixed at 3 months. The cumulated risk of thromboembolic events was calculated using the Kaplan-Meier estimator and a predictive logistic regression model was used to determine risk factors. 3265 patients were eligible for analysis. The mean age was 83.3 ±8.1 years old and 75.6% of patients were female. The mortality was 7.55% (N=112) at 3 months. 98.53% of this cohort received thromboprophylaxis. The cumulated risk for a thromboembolic event was 3.55% at 1 month and 6.41% at 3 months (N=99). There were 9 fatal pulmonary embolisms. 89.19% thromboembolic events occurred within 20 days following surgery. Chronic obstructive pulmonary disease (odds ratio 1.909 [1.179–3.089]), renal failure (odds ratio 1.896 [1.172–3.066]) and the use of a bridge between different types of anticoagulant (odds ratio 2.793 [1.057–7.384]) were associated with TEV. The risk of bleeding was 5.67% at 1 month and 9.38% at 3 months (N=142). 77% of bleeding events were hematomas. The risk of thromboembolic events is higher than expected in a population treated for this condition. Most thromboembolic events occur shortly following surgery. The risk of bleeding is high and most of them are hematomas. Future research could focus on the management of thromboprophylaxis in elderly patients undergoing surgery for a hip fracture

Thromboembolic disease (TED) remains as a major concern for orthopaedic surgeons and is a well-known complication of lower extremity joint replacement procedures. While there is voluminous literature on the topic, it is difficult for the average orthopaedic surgeon to keep up with all the advancements in this area as well as the newer pharmacological options for prophylaxis. To address this, the American Academy of Orthopaedic Surgeons (AAOS) has developed a clinical practice guideline (CPG) in this area to provide treatment recommendations based on the best available evidence. Historically, guidelines for TED prophylaxis have been based largely on randomised controlled trials whose outcome measure was venographically documented deep vein thrombosis (DVT). However, many venographically documented DVTs, particularly those distal to the popliteal vein, are of no clinical consequence. Therefore, in the AAOS CPG the systematic review of the literature was focused on those outcomes that have the most clinical relevance: all-cause mortality, symptomatic or fatal pulmonary embolism (PE), proximal DVT, major bleeding and symptomatic DVT rates. Using these as the clinically important endpoints, it is evident that the extant literature is insufficient to provide definitive guidance in this area and to make specific recommendations about optimal pharmacological prophylaxis. Nonetheless, one strong recommendation has emerged from this systematic review: the guideline recommended against routine post-operative duplex ultrasonography screening of patients who undergo elective hip or knee arthroplasty. Only one risk factor – previous history of TED – had evidence demonstrating a higher risk beyond the risk from elective hip or knee arthroplasty itself (weak recommendation). There was not sufficient evidence that other potential risk factors increase the risk of TED, likely because of the relatively high background risk of elective hip or knee arthroplasty. In addition, there is very little evidence defining populations at increased risk for bleeding and bleeding-associated complications associated with pharmacological prophylaxis. However, the panel did come to a consensus that patients with known bleeding disorders or active liver disease are at an increased risk for post-operative bleeding. In these circumstances, it is recommended that mechanical compressive devices be the primary modality of prophylaxis as pharmacologic prophylaxis may increase the risk of bleeding. There was a moderate strength recommendation for the superiority of neuraxial anesthesia to limit blood loss even though there is no demonstrable effect on the incidence of TED. Finally, there was a moderate grade recommendation that pharmacologic agents (including aspirin) and/or mechanical compression devices be utilised for the prevention of VTE in patients that are undergoing elective hip or knee arthroplasty who are not at elevated risk beyond that of the surgery itself for VTE or bleeding. Clearly there is great need for better evidence with appropriately powered studies that examine the most clinically relevant outcomes in TED prophylaxis

The aim of this study was to compare immediate weight-bearing mobilisation with traditional plaster casting in the rehabilitation of non-operatively treated Achilles tendon ruptures. Forty-eight patients with Achilles tendon rupture were randomised into two groups. The treatment group was fitted with an off-the-shelf carbon-fibre orthotic and the patients were mobilised with immediate full weight-bearing. The control group was immobilised in traditional serial equinus plaster casts. The heel raise within the orthotic and the equinus position of the cast was reduced over a period of eight weeks and then the orthotic or cast was removed. Each patient followed the same rehabilitation protocol. The primary outcome measure was return to the patient's normal activity level as defined by the patient. There was no statistical difference between the groups in terms of return to normal work [p=0.37] and sporting activity [p=0.63]. Nor was there any difference in terms of return to normal walking and stair climbing. There was weak evidence for improved early function in the treatment group. There was 1 re-rupture of the tendon in each group and a further failure of healing in the control group. One patient in the control group died from a fatal pulmonary embolism secondary to a DVT in the ipsilateral leg. Immediate weight-bearing mobilisation provides practical and functional advantages to patients treated non-operatively after Achilles tendon rupture. However, this study provides only weak evidence of faster rehabilitation

Hip and knee arthroplasty has been associated with relatively high rates of thromboembolic events and the majority of UK orthopaedic surgeons use at least one form of prophylaxis. Of the many different subgroups of thromboembolic rates that are commonly presented in the literature, symptomatic proximal deep vein thrombosis (spDVT) and fatal pulmonary embolism (fPE) are perhaps the most important clinical outcomes. To determine the effectiveness of common chemical and mechanical prophylactic methods in preventing spDVT and fPE in patients undergoing primary hip and knee arthroplasty. A systematic review of the literature from 1981 to December 2002 was performed. Predetermined inclusion and exclusion criteria were applied. Studies where more than one method of prophylaxis was used were excluded from analysis. For each individual method of prophylaxis, data was extracted, combined and converted to give estimates of the rates of spDVT, fPE and major bleeding events. Absolute risk reduction estimates for spDVT, fPE and major bleeding events were calculated by comparing the thromboembolic rates for each method of prophylaxis with using no prophylaxis of any kind. 992 studies were identified of which 162 met the inclusion criteria. No method of prophylaxis was statistically significantly more effective at preventing spDVT and fPE than using nothing. There were at least as many major bleeding complications as spDVTs. The number of fPEs prevented was very small. When complications such as major bleeding are considered, the evidence behind the use of any prophylaxis is unconvincing

There is widespread appreciation amongst orthopaedic surgeons of the importance of thromboprophylaxis. However much of the evidence is based on surrogate outcomes of clinical end-points. This population-based study aims to identify the incidence and trends in venous thromboembolic disease (VTE) following total hip (THR) and knee arthroplasty (TKR) with death or readmission for VTE up to two years following surgery for all patients in Scotland as the primary outcome. We used the Scottish Morbidity Record (SMR01) system to identify all patients undergoing hip or knee arthroplasty over the ten-year period from 1992 to 2001. Patients undergoing cataract surgery over the same period were identified as a control group. Record linkage for all patients to subsequent SMR01 and Registrar General records provided details of further admissions due to DVT or non-fatal PE and deaths within Scotland up to two years after the operation. The cause of death was determined from the Registrar General Records. The incidence of VTE (including fatal pulmonary embolism (PE)) three months following primary THR was 2.27% and primary TKR was 1.79%. The incidence of fatal PE within three months of THR was 0.22% and TKR was 0.15%. The majority of events occurred in the interval from hospital discharge to six weeks after surgery. There was no apparent trend over the period. An apparent reduction in the overall mortality within 365 days of surgery appears to be due to a reduction in the incidence of acute myocardial infarct. The data support the current advice that prophylaxis should be continued for at least six weeks following surgery. Despite increased uptake of prophylaxis regimens and earlier mobilisation, there has been no apparent change in the incidence of symptomatic VTE over the ten-years from 1992 to 2001

The purpose of this study is to present the clinical and radiological evaluation of 632 resurfacing total knee arthroplasties of Foundation-Solution type, performed in 550 patients (437 women and 113 men), from 1994 to 2003. In the majority of cases (569 knees) the operation was performed because of degenerative osteoarthritis. Cement-free implantation was performed in 209, cemented in 117 and hybrid implantation in 306 procedures. We were able to retrospectively review 442 (80.4%) of the patients (498 knees), for a follow-up time of 6 months to 10 years. The Knee Insall Rating Scale was improved from 60 points (34–70) preoperatively, to 92 points (74–100) postoperatively. The range of flexion at the latest follow-up was between 75 to 130 degrees (mean 98 degrees). Extension lag more than 10 degrees was found in 3 patients (0.68%). The radiological evaluation was performed according to Knee Society Röentgenographic Evaluation and Scoring System. Partial periprothetic radiolucent lines (< 1mm) were observed in 35 knees (7%), with no statistical significant difference between the three groups and no progression during the follow-up. No further clinical and radiological evidence of mechanical failure and no significant loss of the mechanical axis were noticed. There was a case of fatal pulmonary embolism, and a case of peroneal nerve palsy that fully recovered. Three knees were revised as a result of septic loosening

Venous thrombo-embolism is a common complication following hip replacement. The recently-published pulmonary embolism prevention study reported that aspirin decreased the fatal pulmonary embolism rate in patients with femoral neck fractures. In addition, new products (synthetic factor X-inhibitor Fondaparinux and direct thrombin-inhibiter Desirudin) have been reported to be more effective than low-molecular-weight heparin in preventing asymptomatic DVT. We thought it important to update the 1997 survey on thrombo-embolism prophylaxis by British Orthopaedic Surgeons. A single page questionnaire was sent to 1308 members of the British Orthopaedic Association who are consultant orthopaedic surgeons. Those who did not respond received a reminder. We had a 72% response rate. All surgeons use some form of prophylaxis, with 85% using pharmacological agents. Low-molecular-weight heparin is used by 55% of surgeons, while 20% use only aspirin. Fewer than 1% (five consultants) use early mobilisation and nearly 2% (13 consultants) use graded stockings and early mobilisation as their only prophylactic measures. Unit policies govern 74% of surgeons. In the last 3 years, 30% have changed their regime. Most British orthopaedic surgeons still use pharmacological thromboprophylaxis. The use of aspirin has increased from 5% to 30%. Aspirin is often combined with a mechanical prophylactic. The use of intermittent calf compression has increased from 3% to 22% and of foot pumps from 12% to 19%. The use of low-molecular-weight heparin has fallen by 10%

Purpose: The purpose of this study was to determine the rate of clinically detected deep venous thrombosis and pulmonary embolism in patients with trunk or extremity bone or soft tissue sarcomas. Patients and methods: The clinical records of patients with a confirmed diagnosis of primary bone or soft tissue sarcoma presenting between 1998 and 2003 were reviewed. Data relating to clinical features, risk factors for thromboembolism and clinical thromboembolic events were retrieved. Results: 252 patients were identified. 94 had a diagnosis of primary bone sarcoma and 158 a diagnosis of primary soft tissue sarcoma. The mean age was 53 (range 15 to 94); 137 (54%) were male. 37 patients were suspected clinically of having a deep venous thrombosis, 10 of which were confirmed radiologically, giving a rate of 4%. Nine patients had a suspected pulmonary embolism, 2 of which were confirmed radiologically and one of whom died of pulmonary embolism, giving an overall rate of fatal pulmonary embolism of 0.4%. All patients with thromboembolic events had lower extremity tumours and all were surgical patients. However, the majority of thromboembolic events (6 of 10 deep venous thromboses and 2 of 3 pulmonary embolisms) occurred prior to surgery. Discussion: The risk of a clinically apparent thromboembolic event in patients with bone or soft tissue sarcomas is comparable to that in other orthopaedic patients. Risk factors for venous thromboembolism include lower extremity sarcomas and mechanical obstruction of the venous system. Consideration should be given to excluding deep venous thrombosis before surgery

Total Knee Replacement (TKR) is one of the commonest and successful orthopaedic operations performed in the UK with good long term results. The Natural knee (Sulzer – Centerpulse ) is one of the various types of prostheses available. This implant is unique because of the trochlear notch over the anterior surface of the femoral prosthesis that allows natural tracking of the patella and an asymmetric anatomical tibial component. To our knowledge there are no studies reviewing outcome of Natural Knee Replacement from the UK. We reviewed 177 consecutive TKRs in 147 patients including 30 bilateral simultaneous or staged procedures using Natural Total Knee prosthesis performed during 1994 to 1998, with a minimum of five years follow up. All these surgeries were performed at a single NHS District General Hospital by different grades of surgeons including consultants and trainees. 12 patients died and 10 were lost to follow up. 155 knees were available for final follow up and evaluation. We carried out an outcome related to patient satisfaction using Oxford Knee questionnaire system. We compared the preoperative and post operative scoring using the questionnaire and found an improvement of the score after the procedure. The average improvement in scores before and after surgery was 30 (20 pre op to 50 post op). Out of 155 knees evaluated, 143 knees (92%) were happy with the results while the rest did not have satisfaction with surgery. Complications included anterior knee pain in 12, DVT in 40 , non fatal pulmonary embolism in 2, wound infection in 3, stiffness in 8 of which 5 needed manipulation under anaesthesia, there were 2 revisions of which one knee was done for infection and one for a loose femoral component. Our results suggest that the five year follow-up results of this prosthesis are at par with other commonly used knee replacement prostheses in the UK

Introduction and Aims: Venous Thromboembolism is a common complication following a hip replacement. Recently the pulmonary embolism prevention study was published. It reported that aspirin decreased the fatal pulmonary embolism rate in patients admitted with a fracture neck of femur. In addition, new products (synthetic factor X inhibitor-Fondaparinux, and a direct thrombin inhibiter-Desirudin) have been reported to be more effective than low molecular weight heparin in preventing asymptomatic deep vein thrombosis. We felt it was important to repeat a survey, done in 1997, on the use of thromboembolism prophylaxis among British Orthopaedic Surgeons. Method: A single page questionnaire was sent out to all 1308 consultants – orthopaedic surgeons who were members of the British Orthopaedic Association. Those who did not respond were sent a reminder letter. Results: We achieved a 72% response rate. All surgeons use some form of prophylaxis. Eighty-five percent of surgeons use pharmacological prophylaxis. Low molecular weight heparin is used by 55% of surgeons. Twenty percent of surgeons use aspirin as their only form of pharmacological prophylaxis. Less than 1% (five consultants) use early mobilisation alone and nearly 2% (13 consultants) use graded stockings and early mobilisation as their only form of prophylaxis. Seventy-four percent of surgeons have a unit policy. Thirty percent have changed their regime in the last three years. Conclusion: The majority of British orthopaedic surgeons still use pharmacological thromboprophylaxis. There has been a significant increase in the use of Aspirin, from 5% to 30%. Aspirin is often combined with a mechanical prophylaxis. This has led to an increase in the use of intermittent calf compression (3% to 22%), and foot pumps (12% to 19%). Low molecular weight heparin use has fallen by 10%

Introduction: The C-Stem was introduced in the endeavour to achieve greater stability, improved fixation, minimise subsidence and improve loading of the proximal femur to maintain bone quality and avoid stress shielding. Since promising early results in 2001, no studies including a large patient population from a single surgeon series have been published. Methods: Health records and imaging modalities of 260 patients, operated between 2001 and 2004 were retrospectively evaluated by 2 independent reviewers. All patients had antero-lateral approach in supine position. Clearing of the calcar was carried out to allow adequate cement mantle proximally and posteromedially. Tip of the stem was allowed to penetrate in to the intramedullary bone block. All patients were followed up regularly with clinical and radiological information being updated. Results: 90 men and 170 women, 30 bilateral cases were identified. Mean age at the time of surgery was 61.8 years (50–91). Commonest diagnosis was primary OA (56%) followed by secondary OA due to AVN or childhood pathology (30%) and previous trauma. 43 patients had previous operations in the form of failed internal fixation, osteotomy or hemiarthroplasty. Assessment included oxford hip score. Radiographs digitalised on DICOM software were analysed for subsidence (0.7 mm), alignment (94% satisfactory), bone-cement interface changes (35% progressive improvement) and proximal femur stress shielding (2.1%). At the time of final follow up 89% were independently mobile. 4 % thigh pain, 3 revisions for recurrent dislocations, 3 nonfatal and 2 fatal pulmonary embolism. Taking death or revision for any reason as endpoints, 97.8% survivorship was noted using Kaplan-miere analysis. Discussion: The strength of the study includes large patient population, completeness of follow up and single surgeon series eliminating compounding factors. Bone cement interface improvement was noted in younger patients with high activity level. The study consolidates the soundness of the concept of C-Stem